This article was originally published in The Gray Sheet
Executive SummaryLicense for diffusion tensor magnetic resonance imaging (DT-MRI) technology is granted to GE Medical Systems. Invented by researchers at the National Institute of Child Health and Human Development, the technology "allows physicians and researchers to make detailed, three-dimensional maps of nerve pathways in the brain, heart muscle fibers, and other soft tissue," according to NIH. GEMS will manufacture and market the product, which is expected to increase understanding and diagnosis of such conditions as stroke, amyotrophic lateral sclerosis, multiple sclerosis, autism, attention deficit disorder and schizophrenia. DT-MRI "produces sophisticated images of soft tissues by measuring the three-dimensional random motion of water molecules," NIH explains...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.